Mutation screening in Rett syndrome patients

Fengqing Xiang, Silvia Buervenich, Piero Nicolao, Mark E S Bailey, Zhiping Zhang, Maria Anvret

Department of Clinical Neuroscience,
Karolinska Hospital,
Stockholm, Sweden

F Xiang*
P Nicolao
Z Zhang
M Anvret*

Department of Molecular Medicine,
Karolinska Hospital,
Stockholm, Sweden

F Xiang
S Buervenich
P Nicolao
Z Zhang
M Anvret

Department of Neuroscience,
Karolinska Institute,
Stockholm, Sweden
S Buervenich

Department of Neurology and Psychiatry (Second Neurological Clinic),
University of Padova,
Italy
P Nicolao

Division of Molecular Genetics, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK
M E S Bailey

Correspondence to:
Dr Xiang, Department of Molecular Medicine, Clinical Neurogenetic Unit
CMM-L8-02, Karolinska Hospital, 171 76 Stockholm, Sweden.
Fengqing.Xiang@mm.ki.se

*Present address:
AstraZeneca R&D
Södertälje, 15158 Södertälje, Sweden

Revised version received
3 January 2000
Accepted for publication
26 January 2000

Abstract

Rett syndrome (RTT) was first described in 1966. Its biological and genetic foundations were not clear until recently when Amir *et al* reported that mutations in the *MECP2* gene were detected in around 50% of RTT patients. In this study, we have screened the *MECP2* gene for mutations in our RTT material, including nine familial cases (19 Rett girls) and 59 sporadic cases. A total of 27 sporadic RTT patients were found to have mutations in the *MECP2* gene, but no mutations were identified in our RTT families. In order to address the possibility of further X chromosomal or autosomal genetic factors in RTT, we evaluated six candidate genes for RTT selected on clinical, pathological, and genetic grounds: *UBE1* (human ubiquitin activating enzyme E1, located in chromosome Xp11.23), *UBE2I* (ubiquitin conjugating enzyme E2I, homologous to yeast UBC9, chromosome 16p13.3), *GdX* (ubiquitin-like protein, chromosome Xq28), *SOX3* (SRY related HMG box gene 3, chromosome Xq26-q27), *GABRA3* (γ -aminobutyric acid type A receptor $\alpha 3$ subunit, chromosome Xq28), and *CDR2* (cerebellar degeneration related autoantigen 2, chromosome 16p12-p13.1). No mutations were detected in the coding regions of these six genes in 10 affected subjects and, therefore, alterations in the amino acid sequences of the encoded proteins can be excluded as having a causative role in RTT. Furthermore, gene expression of *MECP2*, *GdX*, *GABRA3*, and *L1CAM* (L1 cell adhesion molecule) was also investigated by in situ hybridisation. No gross differences were observed in neurones of several brain regions between normal controls and Rett patients.

(J Med Genet 2000;37:250–255)

Keywords: Rett syndrome; mutation screening; in situ hybridisation; candidate gene

Rett syndrome (RTT) is a childhood neurodevelopmental disorder that almost exclusively affects females, with a prevalence of approximately 1 in 10 000–15 000.¹ It had been suggested to be a genetic disorder because of the existence of a small number of familial cases, and because it shows a higher degree of concordance in monozygotic (MZ) than dizygotic (DZ) twins.² Rett syndrome is characterised by stereotypical hand movements, loss of acquired skills, breathing dysfunction, gait abnormalities, autistic behaviour, and mental retardation. Besides the “classical RTT” described by Hagberg *et al*³ and Diagnostic

Criteria Working Group,⁴ there also exist non-classical RTT or Rett variants, known as “forme fruste RTT”.⁵ The fact that only females are affected and most cases are sporadic suggested that RTT could be an X linked dominant disease with lethality in affected males. Alternatively, Thomas⁶ hypothesised that a locus on the X chromosome that was prone to a higher rate of mutation during spermatogenesis than during oogenesis could explain these features. Our finding of linkage of RTT to the telomeric region of Xq⁷ is consistent with this model and has recently been validated by other groups.^{8,9}

Recently, mutations in the X linked *MECP2* gene were identified in some RTT patients by Amir *et al*.¹⁰ Methyl-CpG-binding protein 2 (MeCP2) is an abundant chromosomal protein that binds specifically to methylated CpG dinucleotides. The protein consists of a methyl-CpG binding domain (MBD),¹¹ a transcriptional repression domain (TRD),¹² and a corepressor interacting region.¹³ MeCP2 protein selectively binds to methylated CpG dinucleotides in the genome and mediates transcription repression through interaction with histone deacetylase and the corepressor SIN3A.

Because *MECP2* mutations have not been shown in all affected subjects, there is still the possibility of other genetic factors involved in the pathogenesis of RTT, as earlier suggested by Bühler *et al*,¹⁴ including the X chromosome and autosomal loci.

We have therefore confirmed the frequent presence of *MECP2* mutations in our own RTT material and adopted a candidate gene approach for further exclusion of genes involved in RTT. One group of candidates was chosen to examine the possibility that enzymes involved in ubiquitination of proteins might be involved in RTT. Previous studies have shown that mutations in the ubiquitin protein ligase E3A (*UBE3A*) gene cause Angelman syndrome (AS),^{15,16} which is characterised by mental retardation, seizures, hypotonia, epilepsy, absence of speech, and abnormal gait; these phenotypic characteristics overlap those of RTT to a considerable extent. Consequently, we screened three genes involved in the ubiquitination pathways (*UBE1*, *UBE2I*, and *GdX*). *UBE1* catalyses the first step in ubiquitin conjugation. *UBE2I* is essential for cell viability.¹⁷ *GdX* is a housekeeping gene that encodes a protein similar to ubiquitin.¹⁸ Four further genes (*SOX3*, *GABRA3*, *CDR2*, and *L1CAM*) were selected based on their expression patterns or their known roles in neural function. Among all these, three, *GdX*, *GABRA3*, and *L1CAM*, are located in Xq28. We have also found evidence for regions on several autosomes that are concordant in

affected patients from several familial Rett cases (unpublished data). Two of the genes examined here, *UBE2I* and *CDR2*, are located in one of these candidate regions, chromosome 16p12-p13.

SOX3 is closely related to *SRY*, the mammalian sex determining gene on the Y chromosome.¹⁹ The mouse homologue of *SOX3* is expressed at high levels in neuronal tissues during development. The possibility of compensatory expression of the *SRY* gene in males in the presence of a mutated *SOX3* allele on the X chromosome could account for the lack of the RTT phenotype in males and could lead to disease presentation in females only.

GABRA3 is expressed during development of the brain. It also constitutes a good a priori candidate for the site of the biological lesion in Rett syndrome. It is one of the most widely expressed GABA_A receptor subunits during mammalian fetal brain development. However, based on studies in rodents, it is rapidly down-regulated during the first few weeks after birth²⁰⁻²¹ throughout most of its realm of expression, while in a few areas it is present at higher levels in the adult than in the perinatal brain. There is a considerable degree of congruence between the expression domains of *GABRA3* in the late mammalian embryo and the sites of neuronal pathology in Rett syndrome, including deeper cortical layers and brain stem areas involved in the sleep and breathing dysfunction seen in RTT patients.²⁰⁻²⁵

No function has been postulated for *CDR2*, but it is expressed in the nervous system and in neoplasms of ovary, breast, and endometrium. These tissues are oestrogen sensitive, and we have explored the interesting possibility that this pattern of expression might reflect a role for *CDR2* in regulation of sex specific differentiation in the nervous system, another mechanism that might underlie a sex limited disorder.

Additionally, gene expressions of *GdX*, *GABRA3*, *L1CAM*, and *MECP2* were investigated by in situ hybridisation using postmortem brain tissue. The L1 adhesion molecule is expressed mainly on neural cells and is involved in neurone-neurone adhesion and has an important function in the development of the nervous system. Mutations in *L1CAM* have already been shown to lead to X linked mental retardation syndromes, including X linked hydrocephalus (HSAS), MASA syndrome (Mental retardation, Aphasia, Shuffling gait, and Adducted thumbs), X linked complicated spastic paraparesis (SP1), and X linked corpus callosum agenesis (ACC).²⁶

Materials and methods

Ten unrelated patients with "classical" Rett syndrome and normal controls were used in the mutation screening for six candidate genes. For mutation screening of the *MECP2* gene, 59 sporadic cases and nine familial RTT cases were included. Genomic DNA was extracted from blood samples using standard methods. Total RNA was isolated from lymphoblastoid cell lines using the UltraspecTM-II RNA kit (Biotech). First strand cDNA was synthesised using the First-Strand cDNA Synthesis Kit (Pharmacia Biotech). PCR amplification was carried out using standard protocols. The coding region of *SOX3* is GC rich; therefore, a higher temperature (98°C) was used in the denaturing step during each PCR cycle. Primer pairs were designed from published sequences to amplify the entire coding regions of the seven candidate genes (table 1). *Taq* PCR Core Kit (Giagen) was used for *MECP2*-3-2 in order to increase PCR sensitivity. PCR products were isolated from low melting temperature agarose gels and purified using WizardTM PCR Preps DNA Purification System (Promega). Mutation analysis was performed by direct sequencing (Thermo Sequenase radiolabelled terminator cycle sequencing Kit,

Table 1 Primer pairs used in PCR amplification of the seven candidate gene coding regions

Primer pairs	Forward primer (5'-3')	Reverse primer (5'-3')	Annealing temp (°C)
UBE1-1	CAGTCCGTGTTGTCCGA	GCCCGGTTTTTACCGATG	55
UBE1-2	AGGAGGACATCGGTAAAAAC	ACTTGGCGAAGTCCCGTCA	55
UBE1-3	GACTTTGTGGTGACGGAC	GTGTCCATGTCTGTAAACA	55
UBE1-4	AGGGTGGAGAAATCATCG	CTGCCGATGTTGTTCGA	55
UBE1-5	CACCCAGTACTCGAACA	GCTCTGTCTTAAATAGTCG	55
UBE1-6	TCAAACAGTTCCTCGACTATT	GCGGATGGGTGATCGGAC	55
UBE2I	TCCACCTGTCCGCTACGCT	CAATCCCTTCCTTCTGACGAT	59
GdX1-1	ACTTGGCCCGACTGGTTCCT	CCGCACCCCGACCCGACACA	62
GdX1-2	AGTGGACGCCGTCGCGAC	ACACACGGCTGCTGGCCTC	60
GdX2	AGGAGGAACCCATCGATCT	AACACACTTAGTGCGACATGC	57
SOX3-1	AGCTAGAGCCAGGCAGACT	CTTTCTTGAGCAGCGTCTTG	59
SOX3-2	CCGGACTACAAGTACCGACC	GCTGAGAGTGCATGCGCATG	59
SOX3-3	CCATGGGCTCGGTAGTGAAGT	GTGGGGAACAAGGGTGAC	59
GABRA3-1-1	CATCCTTCTCTCCTTTCGCT	GTGTCCGGTGTCCAGATCTT	55
GABRA3-1-2	CTCAGACTGTAGAGCTCGGT	GATTGTTTCAGTGAAGGATC	58
GABRA3-2-1	AGTGAAGACTGACATCTACGTG	GGCACTGATACTCAAGGTG	55
GABRA3-2-2	CAGACATGGCATGATGAAAGA	TGTACGGGCAGGAACAGAC	57
GABRA3-3	TGGCTACTTTGTGATCCAGA	GATGCTTCACGGGTATAC	57
CDR2-1	GCCGAGATGCTGGCGGAAA	GATGACTTCAGCTCCTCCACT	62
CDR2-2	AGATTCTGAGCCTGACTGAAA	AACATACAGAGAGTCTGGCAG	59
CDR2-3	AGGCCAGGTCGCAGAGATG	AGAGAGGCGATAGGCAATAGG	62
MECP2-1	ACACACACTGACCTTTCAGG	AATGTCCCAATAGCCCTGG	60
MECP2-2	CCTGGGCACATACATTTTCCT	TGGCATGTTCTCTGTGATACTT	60
MECP2-3-1	CCCACCCTGAAGCCACGAAACT	CCTGCCCCACCTCCACCTG	67
MECP2-3-2	CTGCTGCTCAAGTCCTGGGGCT	CGACCCTCAGGCCATTCCCAAGA	68
MECP2-3-3	TCCTTCACGGCTTCTTTTGG	TCCTTGTTCTCTTCTGTGTGTC	60

Table 2 Oligonucleotide probes used for in situ hybridisation. Two different probes were used for *GABRA3* and *MECP2*

Gene	Oligonucleotide sequences (5'-3')
<i>GdX</i>	TAGGTTGAGCTTGGAGTTGGGCCCGATGCTATAATCCGAGAGTCGTTTCC
<i>LICAM</i>	TTTCAGCAGCTGCAGGGTCTTGTGTGGTTCTGGTAGGTGACACGGTCGG
<i>GABRA3</i> (1)	CATGGGGCCATCAAATTTTCAGTCTTTCATCATGCCATGTCTGCCGAAA
<i>GABRA3</i> (2)	GGAGATGGTGGAAAATTCAGTGTCTTGGCCAGGTTGATGGGATAGGTGG
<i>MECP2</i> (1)	ACTTCCCAGCAGAGCGGCCAGATTCTCTTGGCTTAAGCTTCCGTGTCCA
<i>MECP2</i> (2)	CAGGGCTCTTACAGGTCTTCAGTCTTCCCGCTCTTCTCACCAGGGT

Amersham Life Science) followed by electrophoresis on 6% denaturing polyacrylamide gels and autoradiography or using Applied Biosystem (ABI) 377 Sequencer. For the six deletions and one insertion detected in this study, both methods were performed to confirm the mutations.

Postmortem brain tissue samples were partly obtained from the Harvard Brain Tissue Resource Center and partly provided by Dr D Armstrong, Baylor College of Medicine, USA. Fresh frozen material from the superior frontal cortex, motor cortex, thalamus, and brain stem of six Rett girls (aged 6 to 17 years) and from seven controls (both males and females, aged 2 to 94 years) was available. Unfixed, 14 µm thick cryosections were made and stored at -20°C until use. Sections were removed from the freezer and air dried five hours before hybridisation. In situ hybridisation was carried out as described elsewhere.²⁸ Briefly, oligonucleotides (table 2) complementary to the four genes of interest and one random nucleotide of similar length (negative control) were 3' end labelled with ³⁵S-dATP (to ensure high sensitivity and accurate cellular localisation) using terminal transferase. Forty ng of labelled oligonucleotide per slide were added to 100 µl of hybridisation cocktail containing 4 × SSC, 50% formamide, 1 × Denhardt's solution, 1% sarcosyl, 0.02 mol/l phosphate buffer (pH 7.0), 10% dextran sulphate, 50 mg sheared salmon sperm DNA, and 200 mmol/l dithiothreitol. Slides were incubated overnight at 42°C in a humidified chamber. Subsequently, the slides were rinsed five times for 45 minutes at 60°C in 1 × SSC, dehydrated through graded ethanol, air dried, dipped in photographic emulsion (Kodak NTB2 at 1:2 dilution), and exposed in the dark for six weeks. After developing, the slides were counterstained with cresyl violet and mounted.

sation cocktail containing 4 × SSC, 50% formamide, 1 × Denhardt's solution, 1% sarcosyl, 0.02 mol/l phosphate buffer (pH 7.0), 10% dextran sulphate, 50 mg sheared salmon sperm DNA, and 200 mmol/l dithiothreitol. Slides were incubated overnight at 42°C in a humidified chamber. Subsequently, the slides were rinsed five times for 45 minutes at 60°C in 1 × SSC, dehydrated through graded ethanol, air dried, dipped in photographic emulsion (Kodak NTB2 at 1:2 dilution), and exposed in the dark for six weeks. After developing, the slides were counterstained with cresyl violet and mounted.

Results

Mutations in the coding region of *MECP2* were found in 35% of our cases. The *MECP2* gene consists of three exons. The whole coding regions including the exon-intron junction were amplified by PCR (~1.5 kb, Genbank accession Nos AF030876 and X99686). Primer information is shown in table 1. Altogether, we identified six deletions (from 7 bp up to 101 bp), one insertion (10 bp), six missense mutations, and three nonsense mutations (table 3) in 27 of 78 patients. Five of the six deletions and the insertion cause frameshifts, and the same mutations were not found in their parents or normal sibs. R106W, D97E, R133C, F157I, and T158M are located in MBD, R306C, R255X, and R294X are located in TRD, and R168X is in the corepressor interacting region. One patient has a 7 bp deletion at nt 1256 and a 70 bp deletion at nt 1172. Another patient has a 10 bp insertion at nt 1127 and a 55 bp deletion at nt 1215. All the deletions and the insertion detected in our patients are clustered in a 150 bp region (nt 1127-1275) which contains tandem repeats. This indicated that the region could be a hot spot for deletion owing to DNA polymerase slippage.

The *UBE1* gene transcript (GenBank accession No M58028) is 3.5 kb in length and we used six pairs of primers to amplify the whole coding sequence (3.2 kb). In contrast, a single pair of primers was used to cover the entire coding region (spanning 476 bp) of *UBE2I* (GenBank accession No U45328). The gene structure of *GdX* is known (Genbank accession No J03589) and primers were therefore designed using intronic sequence to amplify two PCR fragments, each containing two complete exons and the intervening intron. In order to increase the PCR specificity and sensitivity for *GdX*, a two round, nested PCR was used (GDX1-2 in table 1), and in addition, the *Taq* PCR Core kit was used. No mutations were

Table 3 Mutations of *MeCP2* found in this study

Patients No	Mutation type	Region or domain	Nucleotide change*	Amino acid change†
30	Deletion	Poly H+poly P	nt1233(del43)	Frameshift
57	—‡	—	nt1172(del70)	—
—	—	—	nt1256(del7)	—
62	—	Poly H+poly P	nt1170(del101)	—
72	—	—	nt1194(del69)	—
86	—	—	nt1215(del55)	Frameshift
—	Insertion	—	nt1127(ins10)	—
28§	Missense	TRD	990C→T	R306C¶
29§	—	—	—	—
32	—	—	—	—
64	—	—	—	—
67	—	—	—	—
78	—	—	—	—
91	—	—	—	—
39	—	MBD	390C→T	R106W¶
70	—	—	—	—
80	—	—	365C→A	D97E
41	—	—	471C→T	R133C¶
79	—	—	537T→A	F155I
45	—	—	547C→T	T158M¶
18**	Nonsense	TRD	837C→T	R255X¶
42	—	—	—	—
76	—	—	—	—
43	—	—	954C→T	R294X
48	—	—	—	—
55	—	—	—	—
33	—	CRIR††	576C→T	R168X¶
44	—	—	—	—
52	—	—	—	—

*Nucleotide number according to GenBank accession No X99686.

†Amino acid number according to Genbank accession No CAA68001.

‡The same as above.

§Patients 28 and 29 are a twin pair.

¶Same mutation has been reported in ref 10 or ref 28.

**Patient 18 is from a Rett "cluster" family.

††Corepressor interacting region.

Figure 1 Bright field microscopy of neurones in the frontal cortex showing *GABRA3* and *L1CAM* expression. Panels show representative fields from sections from a normal control (A-D) and a Rett patient (E-H). The first (A, E) and the second (B, F) probe for *GABRA3* showed similarly low levels of expression. Relatively strong expression levels were detected with the probe against *L1CAM*. (C, G) Hybridisation with a random oligonucleotide resulted in low background signal (D, H). No differences could be observed between patients and controls for any of the probes used.

Figure 2 Bright field microscopy of neurones in the frontal cortex showing *MECP2* and *L1CAM* expression. Panels show representative fields from sections from a normal control (A-C) and a Rett patient (D-F). *MECP2* (A, D) was expressed at similar levels as *L1CAM* (B, E). The negative control hybridisation (C, F) displays very low background signal. *MECP2* was expressed ubiquitously in patients and controls in all brain tissues tested (besides the prefrontal cortex shown in this figure we also investigated expression in the motor cortex, thalamus, and brain stem, data not shown). No differences in expression between different brain regions or patients versus controls could be detected.

detected in the coding regions of *UBE1*, *UBE2I*, or *GdX*.

SOX3 comprises a single exon. Three pairs of primers were used to amplify and sequence the 1331 bp region containing the coding sequence. An 8 bp insertion (TGCCGCCG) in the gene was identified (between bases 1327 and 1328 of the sequence contained in the Genbank entry with accession number X71135). However, the insertion was present in all 12 subjects tested (10 patients and two normal controls) and the deletion variant may therefore represent an error in the original database sequence.

The coding region of *GABRA3* spans ~1.4 kb (Genbank accession No A28102) and three primer pairs were used to amplify the coding region. The two most 5' fragments were ampli-

fied using a two round, nested PCR strategy to increase PCR specificity and sensitivity. Three pairs of primers were designed to amplify the entire cDNA sequence of *CDR2* (~1.3 kb, Genbank accession No M63256). No mutations were found in either gene.

From the in situ hybridisation experiments, representative photomicrographs are shown in figs 1 and 2. *L1CAM* mRNA was detected at relatively high levels in neurones and lower levels in glia in all brain regions investigated (prefrontal cortex shown in figs 1 and 2, motor cortex, thalamus, and brain stem). A strong ubiquitous signal was generated by *MECP2* specific oligonucleotides (fig 2). Low levels of *GABRA3* and *GdX* expression were found in sections containing tissue from these regions (fig 1). There were no detectable differences in

expression levels or patterns for any of these four genes between Rett patients and controls.

Discussion

Recent evidence from genetic mapping using familial Rett cases has strongly indicated the presence of a gene for RTT in Xq28, finally leading to the discovery of mutations in *MECP2*. Because not all patients investigated so far carry mutations in *MECP2* and because of the clinical variability seen in RTT, it is possible that this disorder may be genetically heterogeneous. In this study, we therefore determined the percentage of our Rett patients with *MECP2* mutations to be 35% and screened further X chromosomal and autosomal candidate genes on the basis of their genomic locations or physiological or genetic characteristics. For some of the candidate genes investigated here, we chose to sequence cDNA products, because full gene structures and sequences were not available for all the genes. In this way, we expected to be able to find mutations in the coding sequence that would be predicted to alter the amino acid sequence of the proteins. This strategy cannot identify mutations in the promoter or 5' or 3' untranslated regions. In addition, truncating mutations that reduce RNA stability might not be apparent. We can be sure that the latter problem was not encountered for most of the genes investigated here, because we were able to show the presence of heterozygous polymorphisms in several subjects (not shown), suggesting that effective biallelic amplification was occurring. It would clearly be desirable to extend these studies to include the remaining parts of these genes, to investigate whether other common types of mutation in these regions play a role.

By screening the *MECP2* gene, 16 mutations were identified including missense mutations, nonsense mutations, an insertion, and deletions. Most of the point mutations are C→T transitions, which are located in the MBD or TRD or corepressor interacting region. The six deletions and one insertion are exclusively clustered within a 150 bp region of exon 3. Surprisingly, we detected two de novo deletions in the "hot spot" region in one patient and one deletion and one small insertion in the same region in another patient. Since it is extremely rare that two de novo mutations happen to occur in a small region and occur twice (two patients), the region is likely to be a hotspot for deletion or insertion. This region contains several tandem repeats; therefore, the region could be unstable owing to DNA polymerase slippage.

The missense mutation R306C was found in seven out of 78 patients (9%). In order to rule out the possibility of a common polymorphism, we used *HhaI* restriction enzyme to test 47 ethnically matched normal controls. None of the 47 normal controls carried this polymorphic site (data not shown). After completely sequencing the entire coding region, mutations were detected in only 35% of patients. There are some mutations that may be missed if they are located in introns, the promoter region, or

the 3' untranslated region or consist of huge deletions. However, we have not identified any mutation in our nine familial RTT cases. Our results indicated that there might be more than one gene for RTT. *MECP2* may play a key role in the development of the disease. Other genes that may interact with *MECP2* or in the same pathway may contribute to the subset of RTT patients remaining unexplained so far.

Skewed X chromosome inactivation has been found in some of our familial RTT cases (paper submitted). The *XIST* gene (X inactive specific transcript), located at the X inactivation centre, XIC, and expressed exclusively from the inactive X chromosome, is thought to be the major gene involved in initiating the process of X chromosome inactivation. Previous studies of two unrelated families with skewed X chromosome inactivation have shown a promoter mutation in the *XIST* in nine females, indicating that there may be an association between alterations in the regulation of *XIST* expression and X chromosome inactivation. We then used the patients with skewed X chromosome inactivation and some other RTT patients without *MECP2* gene mutation to test if there is any mutation in the promoter region of *XIST*. We could not find any mutation in the promoter region of *XIST* in any of the 10 patients tested (data not shown).

We also used in situ hybridisation to investigate the expression levels of a set of candidate genes. We predicted that mutations in these genes that caused gross alterations in transcription rates or in mRNA stability or localisation would be detected by this technique. The ability to detect such changes might be of use in narrowing down the search for candidates on which to perform a mutation scan. In the case of *MECP2*, changes in regional or global expression levels may be important clues for an understanding of the pathogenetic mechanisms underlying the syndrome. We observed no gross alterations of expression levels in the four genes tested (*GABRA3*, *GdX*, *L1CAM*, and *MECP2*), but two of them, *GABRA3* and *GdX*, were expressed at relatively low levels and subtle changes in expression pattern or levels in patients would therefore be difficult to detect. When using postmortem material, there is the added danger that global degrading processes acting on mRNA will have proceeded too far to be able to detect transcripts. In this study, we detected high levels of *L1CAM* and *MECP2* transcripts, suggesting that this problem did not occur in our samples.

We thank all the patients and their families for their participation, all doctors who provided the sample materials, Dr Nessa Carey and Dr Mark G Darlison for helpful comments, Dr Laurent Villard for helping design primers for *MECP2* exon 1, and Mrs Ann-Christin Thelander for excellent technical assistance. This work is supported by the Axel and Margaret Axson Johnson Foundation, the Emil and Wera Cornell Foundation, the Ragnar Söderberg Foundation, the International Rett Syndrome Association, and Karolinska Institutet, NIMH and USPHS funds. Brain tissues were provided by the Harvard Brain Tissue Resource Center, which is supported in part by PHS grant number MH/NS 31862.

1 Hagberg B. Rett syndrome: prevalence and impact on progressive severe mental retardation in girls. *Acta Paediatr Scand* 1985;74:405-8.

- 2 Wahlström J. Practical and theoretical considerations concerning the genetics of the Rett syndrome. *Brain Dev* 1987;9:466-8.
- 3 Hagberg B, Witt-Engerström I. Rett syndrome: a suggested staging system for describing impairment profile with increasing age towards adolescence. *Am J Med Genet* 1986;24(suppl 1):47-59.
- 4 The Rett Syndrome Diagnostic Working Group. Diagnostic criteria for Rett syndrome. *Ann Neurol* 1988;23:425-8.
- 5 Hagberg B, Anvret M, Wahlström J, eds. *Rett syndrome - clinical and biological aspects*. London: Mac Keith Press, 1995.
- 6 Thomas GH. High male:female ratio of germ-line mutation: an alternative explanation for postulated gestational lethality in males in X-linked dominant disorders. *Am J Hum Genet* 1996;58:1364-8.
- 7 Xiang F, Zhang Z, Clarke A, et al. Chromosome mapping of Rett syndrome: a likely candidate region on the telomere of Xq. *J Med Genet* 1998;35:297-300.
- 8 Sirianni N, Naidu S, Pereira J, Pillotto RF, Hoffman EP. Rett syndrome: confirmation of X-linked dominant inheritance, and localization of the gene to Xq28. *Am J Hum Genet* 1998;63:1553-8.
- 9 Webb T, Clarke A, Hanefeld F, Pereira JL, Rosenbloom L, Woods CG. Linkage analysis in Rett syndrome families suggests that there may be a critical region at Xq28. *J Med Genet* 1998;35:997-1003.
- 10 Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked *MECP2*, encoding methyl-CpG-binding protein 1. *Nat Genet* 1999;23:185-8.
- 11 Nan X, Meehan RR, Bird A. Dissection of the methyl-CpG binding domain from the chromosomal protein MeCP2. *Nucleic Acids Res* 1993;21:4886-92.
- 12 Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. *Cell* 1997;88:471-81.
- 13 Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. *Nature* 1998;393:386-9.
- 14 Bühler EM, Malik NJ, Alkan M. Another model for the inheritance of Rett syndrome. *Am J Med Genet* 1990;36:126-31.
- 15 Kishino T, Lalande M, Wagstaff J. UBE3A/E6-AP mutations cause Angelman syndrome. *Nat Genet* 1997;15:70-3.
- 16 Matsuura T, Sutcliffe JS, Fang P, et al. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome. *Nat Genet* 1997;15:74-7.
- 17 Jentsch S. The ubiquitin-conjugation system. *Annu Rev Genet* 1992;26:179-207.
- 18 Toniolo D, Persico M, Alcalay M. A "housekeeping" gene on the X chromosome encodes a protein similar to ubiquitin. *Proc Natl Acad Sci USA* 1988;85:851-5.
- 19 Stevanovic M, Lovell-Badge R, Collignon J, Goodfellow PN. *SOX3* is an X-linked gene related to *SRY*. *Hum Mol Genet* 1993;2:2013-18.
- 20 Laurie DJ, Wisden W, Seeburg PH. The distribution of thirteen GABA_A receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. *J Neurosci* 1992;12:4151-72.
- 21 Araki T, Tohyama M. Region-specific expression of GABA_A receptor $\alpha 3$ and $\alpha 4$ subunits mRNAs in the rat brain. *Mol Brain Res* 1992;12:293-314.
- 22 Naidu S. Rett syndrome: a disorder affecting early brain growth. *Ann Neurol* 1997;42:3-10.
- 23 Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of thirteen GABA_A receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. *J Neurosci* 1992;12:1040-62.
- 24 Laurie DJ, Seeburg PH, Wisden W. The distribution of thirteen GABA_A receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. *J Neurosci* 1992;12:1063-76.
- 25 Chang CCA, Luntz-Leybman V, Evans JE, Rotter A, Frostholt A. Developmental changes in the expression of γ -aminobutyric acid/benzodiazepine receptor subunit mRNAs in the murine inferior olivary complex. *J Comp Neurol* 1995;356:615-28.
- 26 Van Camp G, Fransen E, Vits L, Raes G, Willems PJ. A locus-specific mutation database for the neural cell adhesion molecule *L1CAM* (Xq28). *Hum Mutat* 1996;8:391.
- 27 Dagerlind Å, Friberg K, Bean AG, Hökfelt T. Sensitive mRNA detection using unfixed tissue: combined radioactive and non-radioactive in situ hybridization histochemistry. *Histochemistry* 1992;98:39-49.
- 28 Wan M, Lee SS, Zhang X, et al. Rett syndrome and beyond: recurrent spontaneous and familial *MECP2* mutations at CpG hotspots. *Am J Hum Genet* 1999;65:1520-9.